In a twelve-month clinical trial in fifty-five NAFLD patients, it was shown that metformin (2 g/day) was better than a prescriptive weight reducing diet for reduction of ALT levels (30). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.